{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:45:49Z","timestamp":1786981549790,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T00:00:00Z","timestamp":1488844800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T00:00:00Z","timestamp":1488844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["TL1 TR 001084"],"award-info":[{"award-number":["TL1 TR 001084"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010293","name":"Seattle Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010293","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Haas Family Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s11060-017-2389-9","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T17:59:52Z","timestamp":1488909592000},"page":"439-446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and S\u00e9zary Syndrome"],"prefix":"10.1007","volume":"132","author":[{"given":"Zachary A.","family":"Corbin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Nguyen-Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziba","family":"Rahbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahkam","family":"Tavallaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin A.","family":"Salva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary S.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Nagpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,7]]},"reference":[{"issue":"3","key":"2389_CR1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s10549-010-1278-0","volume":"125","author":"DL Hershman","year":"2010","unstructured":"Hershman DL, Weimer LH, Wang A et al (2010) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125(3):767\u2013774. doi:\n                    10.1007\/s10549-010-1278-0","journal-title":"Breast Cancer Res Treat"},{"key":"2389_CR2","volume-title":"Neurologic complications of cancer","author":"LM DeAngelis","year":"2009","unstructured":"DeAngelis LM, Posner JB (2009) Neurologic complications of cancer, 2nd\u00a0edn. Oxford University Press, Oxford","edition":"2"},{"issue":"18","key":"2389_CR3","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","volume":"32","author":"DL Hershman","year":"2014","unstructured":"Hershman DL, Lacchetti C, Dworkin RH et al (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 32(18):1941\u20131967. doi:\n                    10.1200\/JCO.2013.54.0914","journal-title":"J Clin Oncol"},{"issue":"3","key":"2389_CR4","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.410350310","volume":"35","author":"V Chaudhry","year":"1994","unstructured":"Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35(3):304\u2013311. doi:\n                    10.1002\/ana.410350310","journal-title":"Ann Neurol"},{"key":"2389_CR5","doi-asserted-by":"crossref","unstructured":"Cornblath DR, Chaudhry V, Carter K et al. Total neuropathy score: validation and reliability study. Neurology. 1999;53(8):1660\u20131664. \n                    http:\/\/www.neurology.org.laneproxy.stanford.edu\/content\/53\/8\/1660.full#ref-12","DOI":"10.1212\/WNL.53.8.1660"},{"issue":"2","key":"2389_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1085-9489.2006.00078.x","volume":"11","author":"G Cavaletti","year":"2006","unstructured":"Cavaletti G, Jann S, Pace A et al (2006) Multi-center assessment of the total neuropathy score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 11(2):135\u2013141. doi:\n                    10.1111\/j.1085-9489.2006.00078.x","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"2389_CR7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","volume":"12","author":"G Cavaletti","year":"2007","unstructured":"Cavaletti G, Frigeni B, Lanzani F et al (2007) The total neuropathy score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 12(3):210\u2013215. doi:\n                    10.1111\/j.1529-8027.2007.00141.x","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"2389_CR8","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/annonc\/mds329","volume":"24","author":"G Cavaletti","year":"2013","unstructured":"Cavaletti G, Cornblath DR, Merkies ISJ et al (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24(2):454\u2013462. doi:\n                    10.1093\/annonc\/mds329","journal-title":"Ann Oncol"},{"issue":"6","key":"2389_CR9","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"E Olsen","year":"2007","unstructured":"Olsen E, Vonderheid E, Pimpinelli N et al (2007) Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110(6):1713\u20131722. doi:\n                    10.1182\/blood-2007-03-055749","journal-title":"Blood"},{"issue":"7","key":"2389_CR10","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/archderm.139.7.857","volume":"139","author":"YH Kim","year":"2003","unstructured":"Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT (2003) Long-term outcome of 525 patients with mycosis fungoides and S\u00e9zary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 139(7):857\u2013866. doi:\n                    10.1001\/archderm.139.7.857","journal-title":"Arch Dermatol"},{"issue":"3","key":"2389_CR11","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","volume":"16","author":"NM Okeley","year":"2010","unstructured":"Okeley NM, Miyamoto JB, Zhang X et al (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 16(3):888\u2013897. doi:\n                    10.1158\/1078-0432.CCR-09-2069","journal-title":"Clin Cancer Res"},{"key":"2389_CR12","volume-title":"Additional, non-classical antibody-drug conjugate functions contribute to the antitumor activity of brentuximab vedotin","author":"SJ Gardi","year":"2016","unstructured":"Gardi SJ, Heiser R, Cao A et al (2016) Additional, non-classical antibody-drug conjugate functions contribute to the antitumor activity of brentuximab vedotin. ASH Meeting on Lymphoma Biology. Colorado Springs, CO"},{"issue":"21","key":"2389_CR13","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.1158\/1078-0432.CCR-12-1803","volume":"18","author":"RA de Claro","year":"2012","unstructured":"de Claro RA, McGinn K, Kwitkowski V et al (2012) U.S. food and drug administration approval summary: brentuximab vedotin for the treatment of relapsed hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 18(21):5845\u20135849. doi:\n                    10.1158\/1078-0432.CCR-12-1803","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2389_CR14","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363(19):1812\u20131821. doi:\n                    10.1056\/NEJMoa1002965","journal-title":"N Engl J Med"},{"issue":"18","key":"2389_CR15","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol 30(18):2183\u20132189. doi:\n                    10.1200\/JCO.2011.38.0410","journal-title":"J Clin Oncol"},{"issue":"18","key":"2389_CR16","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30(18):2190\u20132196. doi:\n                    10.1200\/JCO.2011.38.0402","journal-title":"J Clin Oncol"},{"issue":"32","key":"2389_CR17","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","volume":"33","author":"M Duvic","year":"2015","unstructured":"Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R (2015) Results of a phase II trial of brentuximab vedotin for CD30 + cutaneous T cell lymphoma and lymphomatoid papulosis. J Clin Oncol 33(32):3759\u20133765. doi:\n                    10.1200\/JCO.2014.60.3787","journal-title":"J Clin Oncol"},{"issue":"32","key":"2389_CR18","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","volume":"33","author":"YH Kim","year":"2015","unstructured":"Kim YH, Tavallaee M, Sundram U et al (2015) Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol 33(32):3750\u20133758. doi:\n                    10.1200\/JCO.2014.60.3969","journal-title":"J Clin Oncol"},{"key":"2389_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/0471142727.mb1419s84","volume-title":"Visualization of microscopy-based spectral imaging data from multi-label tissue sections","author":"JR Mansfield","year":"2001","unstructured":"Mansfield JR, Hoyt C, Levenson RM (2001) Visualization of microscopy-based spectral imaging data from multi-label tissue sections. Wiley, Hoboken, pp\u00a01\u201315. doi:\n                    10.1002\/0471142727.mb1419s84"},{"key":"2389_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/CMAR.S44261","volume":"2014","author":"A Argyriou","year":"2014","unstructured":"Argyriou A, Kyritsis A, Makatsoris T, Kalofonos H (2014) Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. CMAR 2014:135\u2013213. doi:\n                    10.2147\/CMAR.S44261","journal-title":"CMAR"},{"issue":"10","key":"2389_CR21","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1002\/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G","volume":"73","author":"N Haim","year":"1994","unstructured":"Haim N, Epelbaum R, Ben-Shahar M, Yarnitsky D, Simri W, Robinson E (1994) Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 73(10):2515\u20132519","journal-title":"Cancer"},{"issue":"suppl 4","key":"2389_CR22","doi-asserted-by":"publisher","first-page":"iv45","DOI":"10.1093\/neuonc\/nos203","volume":"14","author":"W Grisold","year":"2012","unstructured":"Grisold W, Cavaletti G, Windebank AJ (2012) Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 14(suppl 4):iv45\u2013iv54. doi:\n                    10.1093\/neuonc\/nos203\n                    \n                  .","journal-title":"Neuro Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-017-2389-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-017-2389-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-017-2389-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T03:24:19Z","timestamp":1589685859000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-017-2389-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,7]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["2389"],"URL":"https:\/\/doi.org\/10.1007\/s11060-017-2389-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,7]]},"assertion":[{"value":"28 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Author Y Kim has received research grants from Seattle Genetics. All remaining authors declare they have no conflict of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Author Z Corbin was funded by a TL1 Clinical Research Training Program award from Stanford Spectrum \u00a0(NIH TL1 TR 001084).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}